Neos Therapeutics Inc. (NEOS) Trading 4.4% Higher
Neos Therapeutics Inc. (NASDAQ:NEOS) shares traded up 4.4% on Friday . The stock traded as high as $7.70 and last traded at $7.59, with a volume of 109,619 shares traded. The stock had previously closed at $7.27.
Several research analysts have recently weighed in on the company. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Neos Therapeutics in a research report on Wednesday, May 18th. Zacks Investment Research raised Neos Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research report on Thursday, April 21st. Royal Bank Of Canada reduced their price target on Neos Therapeutics from $33.00 to $29.00 and set an “outperform” rating for the company in a research report on Tuesday, May 17th. Finally, BMO Capital Markets reissued a “buy” rating and set a $15.00 price target on shares of Neos Therapeutics in a research report on Tuesday, July 19th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Neos Therapeutics currently has a consensus rating of “Buy” and an average target price of $21.75.
The company’s 50-day moving average is $8.92 and its 200 day moving average is $9.67. The company’s market capitalization is $117.61 million.
Neos Therapeutics (NASDAQ:NEOS) last announced its earnings results on Thursday, August 11th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.16) by $0.49. The company earned $1.49 million during the quarter, compared to analyst estimates of $1.48 million. Equities analysts predict that Neos Therapeutics Inc. will post ($4.98) EPS for the current fiscal year.
In other Neos Therapeutics news, insider Juergen Martens acquired 10,000 shares of the stock in a transaction dated Monday, June 13th. The stock was purchased at an average cost of $9.90 per share, with a total value of $99,000.00. Following the transaction, the insider now owns 10,000 shares in the company, valued at approximately $99,000. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director Gregory J. Robitaille acquired 7,442 shares of the stock in a transaction dated Wednesday, May 18th. The stock was acquired at an average cost of $7.55 per share, with a total value of $56,187.10. Following the completion of the transaction, the director now owns 55,677 shares in the company, valued at approximately $420,361.35. The disclosure for this purchase can be found here.
A hedge fund recently raised its stake in Neos Therapeutics stock. Marshall Wace LLP raised its stake in Neos Therapeutics Inc. (NASDAQ:NEOS) by 11.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 96,162 shares of the company’s stock after buying an additional 9,929 shares during the period. Marshall Wace LLP owned 0.60% of Neos Therapeutics worth $1,377,000 at the end of the most recent quarter.
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.